Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10039136HBVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS30073496HIVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS30073497HIVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20011278HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029983HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029984HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029985HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029986HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029987HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20064469HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TCGA Plot Options
Drug Information
GeneHTR2C
DrugBank IDDB01392
Drug NameYohimbine
Target IDBE0000533
UniProt IDP28335
Regulation Typeantagonist
PubMed IDs8032658; 6136920; 20036429
CitationsBaxter GS, Murphy OE, Blackburn TP: Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol. 1994 May;112(1):323-31.@@Kaumann AJ: Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1983 Jun;323(2):149-54.@@Holmes A, Quirk GJ: Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine. Trends Pharmacol Sci. 2010 Jan;31(1):2-7. doi: 10.1016/j.tips.2009.10.003. Epub 2009 Dec 28.
GroupsApproved; Investigational; Vet_approved
Direct ClassificationYohimbine alkaloids
SMILES[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2
Pathways
PharmGKBPA451946
ChEMBLCHEMBL15245